Af­ter Phase 3 win, Ar­row­head­'s RNAi chas­es Io­n­is to mar­ket en­try in rare ge­net­ic dis­or­der

Ar­row­head Phar­ma­ceu­ti­cals’ RNAi treat­ment has suc­ceed­ed in a reg­is­tra­tional test in pa­tients with an ul­tra-rare lipid me­tab­o­lism dis­or­der, bol­ster­ing plans for a reg­u­la­to­ry fil­ing that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER